Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.
about
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infectionHyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designNovel approaches to inhibit HIV entryAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesReconstitution of the ancestral glycoprotein of human endogenous retrovirus k and modulation of its functional activity by truncation of the cytoplasmic domainHuman Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B EnvelopeHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesRecent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Evolution of the uniquely adaptable lentiviral envelope in a natural reservoir host.Generation of random mutant libraries with multiple primers in a single reactionComparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopesInduction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope GlycoproteinsComparing antigenicity and immunogenicity of engineered gp120.Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4.Siglecs facilitate HIV-1 infection of macrophages through adhesion with viral sialic acids.Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicityVariable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.Membrane fusion and cell entry of XMRV are pH-independent and modulated by the envelope glycoprotein's cytoplasmic tailConsistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaquesProperties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses.LCMV glycosylation modulates viral fitness and cell tropism.HIV-1 envelope glycan moieties modulate HIV-1 transmission.Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.Role of N glycosylation of hepatitis B virus envelope proteins in morphogenesis and infectivity of hepatitis delta virusThe CD8-derived chemokine XCL1/lymphotactin is a conformation-dependent, broad-spectrum inhibitor of HIV-1.Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.Functional effects of coxsackievirus and adenovirus receptor glycosylation on homophilic adhesion and adenoviral infection.Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formationAntigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine.Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responsesConserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding SitesAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Antibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response.Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies.
P2860
Q24538985-D472DA6A-9915-48F6-AF1A-4F3267C97FEEQ24679395-B9F95E42-576D-4024-88A4-3AAC7CC2B19AQ27013957-1F686E67-E353-4C2D-B343-F124EAF3A886Q27489000-6C883033-C409-4BB2-9E3B-932F30AA8334Q28749689-0FB80780-3E6B-4FD3-8EEB-EB06D4D2A33EQ29307502-3DBC9195-B51F-4560-98BD-B02A2CA047F0Q29619015-657EDD93-9DB8-46D9-9AB6-01DCA8637C19Q30353580-A38662D7-29CB-41CA-95FB-C012077558A8Q30379200-F5B55776-178C-47EB-88FA-DAB82F688DC7Q31034710-9D8DD379-B45E-4E57-BD45-67D0B323B153Q33548933-FB4553B9-FD16-46B1-9160-F25DB4EA9EACQ33648910-E161A4DC-9D8E-48E0-B72F-DCF8575B656CQ33724169-F0689C02-4975-4925-9D48-E68E4A000DAFQ33843345-95B29C30-DFFD-42A3-81AB-62C9B614FC78Q33911809-45BE4B9D-0CD2-4FBD-95D7-944B4784FD05Q33960361-D0A9E16A-F19A-4963-A718-8964DB53426CQ33984309-46F33D57-6799-48B9-8497-906DE43637A4Q33984371-C56F7964-00BD-47E4-9986-BE28A72A9B27Q34023679-99F2D56C-1B5E-4D88-8D88-B4543A37BFDAQ34175370-FE0BF7E1-EEA9-4AED-9FF5-6589C4BE46F8Q34178201-27AEBBB2-16B1-4011-841A-4FD244CDC33FQ34221609-1CC8BCC6-108F-448B-B559-451C62AA68E0Q34301728-7DA06744-9B94-4B70-BCCA-B0576F3FC3E3Q34317031-DEE45E57-EC37-4D50-A9A5-6CB4EFC439E8Q34544878-0CDFAA41-CF31-4050-BA9A-30190BBB74F0Q34595009-D27B4174-5508-427C-8947-74603168897FQ34637968-0E1887A7-94DB-4E50-9BDB-1EB8AEA381C9Q34976217-528367AB-86A2-4DBC-906B-B114C8BEC1A8Q35079838-2555ED69-E7BD-44D1-80CC-4CBF09242C1CQ35542887-285EC3B8-15F5-43C5-9DDC-E4DE542BC0EBQ35666057-E38A1101-FF2D-477A-83FC-B215A6CC472CQ35857655-E9F3B415-D23C-44D9-9DB9-FE5A48274753Q35893538-DD58D19B-CCEB-4F48-92EE-C5A3466D3FB7Q35933555-72CAF21B-DB39-4077-B70B-43C4A00DA269Q36157711-B5BC446B-9EFC-42AA-9656-BA99DEB18295Q36424574-37E3108A-FB76-4FE8-A293-34574EEFC039Q36434294-56F626F2-37F4-44F4-87D3-2A77A695831BQ36600380-CF62B7D2-E99E-4730-BBC4-5393D5A83224Q36823297-248C0152-3E0B-4020-B100-9C254010574DQ36994698-44E64B48-B4F6-48B2-A1A5-65C98D23A975
P2860
Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Role of N-linked glycans in a ...... eutralizing antibody response.
@ast
Role of N-linked glycans in a ...... eutralizing antibody response.
@en
Role of N-linked glycans in a ...... eutralizing antibody response.
@nl
type
label
Role of N-linked glycans in a ...... eutralizing antibody response.
@ast
Role of N-linked glycans in a ...... eutralizing antibody response.
@en
Role of N-linked glycans in a ...... eutralizing antibody response.
@nl
prefLabel
Role of N-linked glycans in a ...... eutralizing antibody response.
@ast
Role of N-linked glycans in a ...... eutralizing antibody response.
@en
Role of N-linked glycans in a ...... eutralizing antibody response.
@nl
P2093
P2860
P1433
P1476
Role of N-linked glycans in a ...... eutralizing antibody response.
@en
P2093
John K Rose
Linda Buonocore
Miriam I Quiñones-Kochs
P2860
P304
P356
10.1128/JVI.76.9.4199-4211.2002
P407
P577
2002-05-01T00:00:00Z